Research programme: psychiatric and neurological disorders therapeutics - Neuronascent

Drug Profile

Research programme: psychiatric and neurological disorders therapeutics - Neuronascent

Alternative Names: NNI-351

Latest Information Update: 20 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuronascent
  • Class Small molecules
  • Mechanism of Action DYRK kinase inhibitors; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Down syndrome; Major depressive disorder; Post-traumatic stress disorders

Most Recent Events

  • 14 Nov 2017 Neuronascent has composition of matter patent protection for oral neuron regenerative technology in Europe
  • 24 Jan 2017 Preclinical development for Down syndrome, Post-traumatic stress disorder and Major depressive disorder is ongoing in USA
  • 24 Jan 2017 Neuronascent has patent protection for several new groups of compounds treating neurological conditions in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top